Latest stories on CTOR
CITIUS ONCOLOGY, INC. (CTOR) files 8-K
SEC 8-K50 · neutralgeneral
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment
PR Newswire67 · bullishproduct/pr
Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption
PR Newswire56 · neutralproduct/pr
Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption
StockTitan63 · neutralproduct/pr
Citius Oncology Highlights Promising LYMPHIR Combo Phase 1 Data
TipRanks63 · neutralproduct/pr
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
PR Newswire59 · neutralearnings